Compare Johnson & Johnson (JNJ) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs WD 40 Company — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while WD 40 Company trades at $202.29 (market cap $2.73B). The key difference: Johnson & Johnson is far larger — about 226.4× WD 40 Company's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and WD 40 Company for 22 Days on average.
| JNJ | WDFC | |
|---|---|---|
Market Cap | $618.09B | $2.73B |
Volume | 6,050,983 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $264.91 |
52-Week Low | $186.00 | $187.52 |
Typical Hold Time | 129 Days | 22 Days |
Enterprise Value | $646.37B | $2.79B |
Dividend Yield | 2.09% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
WDFC trades at $202.29, showing modest daily gains. The technical outlook is bullish, supported by moving averages, while recent earnings have largely beaten expectations. The company maintains strong profitability with a 13.22% net income margin and a 33.22% ROE, though valuation multiples like a P/E of 30.96 appear elevated. Positive news highlights strategic growth initiatives and institutional buying interest.
The stock presents a mixed outlook; robust fundamentals and growth strategy support upside, but high valuation and margin pressures from input costs pose risks. Analyst consensus is cautious with a majority hold rating, indicating balanced but not aggressive investor sentiment near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
